$IOVA

Amylyx Pharmaceuticals (AMLX) surged 63% after reporting positive Phase 3 trial results for avexitide, with Stifel doubling its price target to $45. Iovance Biotherapeutics (IOVA) hit a 52-week high, driven by Q2 earnings and a price target increase from Mizuho. ONEOK (OKE) reached a 52-week high following strong Q2 earnings, raised 2026 guidance, and a new supply deal, with Morgan Stanley raising its target to $105.

Iovance Biotherapeutics (IOVA) reported early clinical trial results showing lifileucel, its tumor-infiltrating lymphocyte therapy, achieved tumor responses in half of six evaluable patients with advanced soft tissue sarcomas. The company plans a registrational trial and FDA consultation for expedited review. IOVA stock rose over 5% in premarket trading. Q4 revenue was $87M, up 30% YoY, with a 50% gross margin. IOVA stock has fallen 47% over the past year.

Iovance Biotherapeutics (IOVA) granted 20 new employees options for 240,135 shares at $8.99 each, the closing price on August 20, 2026. The options vest over three years, with one-third vesting after one year and the rest in quarterly installments. The company operates under NASDAQ Listing Rule 5635(c)(4).

Iovance Biotherapeutics (IOVA) surged 12% to a 52-week high after reporting Q2 revenue of $99.3M and a UBS price target raise. Amylyx Pharmaceuticals (AMLX) rose 2% on positive Phase 3 trial results and a $500M offering. ConocoPhillips (COP) gained 3% after strong Q2 earnings and a Morgan Stanley price target increase.

Journey Medical (DERM) rose 13% on strong Q2 results, with revenue up 23% to $18.5M. Iovance (IOVA) gained 11% on 66% revenue growth to $99.3M. Caris (CAI) advanced 8% after raising 2026 revenue guidance to $1.03B-$1.04B. Prelude (PRLD) up 8% on narrower Q2 loss. Compugen (CGEN) gained 7% on COM701 trial progress. Conexeu (CNXU) rose 4% on regenerative aesthetics market opportunity.

Iovance Biotherapeutics (IOVA) reported Q2 revenue of $99.313M, beating estimates of $87.832M. The company's stock hit a 52-week high, up over 200% year-to-date. Amtagvi, its approved therapy, drove most of the revenue. The company reaffirmed its 2026 sales guidance of $350M to $370M. Analysts adjusted price targets, with UBS raising its target to $7 and Mizuho to $11.

Iovance Biotherapeutics (IOVA) stock rose 8.32% after Q2 2026 revenue of $99.3M exceeded expectations of $87.8M, driven by strong Amtagvi sales. EPS loss of $0.11 was better than expected. The company has $304M in cash and expects it to last until 2H 2028. Analysts have raised price targets, with an average of $9.33.

Biotech shares hit 52-week highs on Aug. 17, 2026. OmniAb (OABI) rose to $4.29 after raising 2026 cash flow guidance; Q2 revenue was $13.4M. Iovance (IOVA) reached $7.25 on Q2 revenue growth to $66M and Amtagvi sales. Revolution (RVMD) hit $215.97 on Phase 3 RASolute data for Daraxonrasib. BioLife (BLFS) hit $35.46 after Repligen (RGEN) agreed to buy it for about $1.5B.

Iovance Biotherapeutics (IOVA) shares hit a 52-week high of $6.94 and last traded around $6.96. The article cites 12-month revenue of $325 million (up 35% YoY) and Q2 2026 results: adjusted loss of $0.11 per share vs $0.13 expected, and revenue of $99.31 million vs $87.12 expected, driven by Amtagvi sales.

Iovance Biotherapeutics (NASDAQ:IOVA) reported Q2 2026 revenue of $99.3M, up 66% YoY, driven by Amtagvi. Amtagvi revenue was $91M. Gross margin rose to 56%. Cash and investments were $304M, expected to fund operations into H2 2028. Full-year 2026 revenue guidance was $350M to $370M; management may update it in Q3.